Amniocentesis Explained: Risks, Benefits, and When to Consider the Test
Translated & summarized from Srugim by baba
Amniocentesis, a diagnostic prenatal test analyzing fetal cells from amniotic fluid, is now funded by Israel's Ministry of Health for women 32 and older. The procedure, performed between 16-22 weeks, carries a miscarriage risk estimated at 0.1%-0.25%. Results from the standard chromosomal microarray test are usually available within three weeks. The decision to undergo the test should be based on personal understanding and consultation with medical professionals.
The story in 6 lines · by baba
- Amniocentesis analyzes fetal cells from amniotic fluid for genetic abnormalities.
- The miscarriage risk from amniocentesis is now estimated at 0.1% to 0.25%.
- Israel's Ministry of Health funds the test for women aged 32 and older.
- The standard test in Israel is the chromosomal microarray (CMA).
- Full CMA results typically take two to three weeks to process.
- The decision to have the test is personal and requires medical consultation.
Amniocentesis, a widely discussed prenatal test, involves extracting amniotic fluid surrounding the fetus to analyze fetal cells for genetic abnormalities. Typically performed between 16 and 22 weeks of pregnancy, the procedure uses a thin needle guided by ultrasound to withdraw fluid, which the body replenishes within hours. The sample is sent to a genetic lab, where the standard test in Israel is the chromosomal microarray (CMA), which detects small genetic deficiencies or additions beyond basic chromosome counts. Additional tests like whole exome sequencing can also be performed.
It is crucial to understand that amniocentesis diagnoses only what is tested for and does not guarantee a baby free of all diseases or defects; structural abnormalities are checked through system scans. Unlike screening tests such as NIPT, which assess risk without invasiveness, amniocentesis is diagnostic, providing definitive answers at the cost of a small risk. The Ministry of Health in Israel now funds the test for all women aged 32 and over, acknowledging that while Down syndrome risk increases with maternal age, most affected babies are born to younger mothers due to higher birth rates. Genetic deficiencies are not age-dependent.
The risk of miscarriage associated with amniocentesis is estimated today at 0.1% to 0.25%, significantly lower than older figures of 1 in 200. International studies suggest a procedure-related risk of around 0.3%. The skill of the practitioner, especially with continuous ultrasound guidance, is a key factor in minimizing this risk. Women with Rh-negative blood type receive an Anti-D injection post-procedure to prevent antibody formation that could harm the fetus.
Results are typically delivered in two stages: a rapid test within one to three days ruling out common chromosomal disorders like Down syndrome, and the full CMA results within two to three weeks. More extensive tests may take longer. The article emphasizes that the decision to undergo amniocentesis is personal and should be made after thorough understanding and consultation with a genetic counselor or medical expert, considering individual risks and what will be done with the results.